Last update 31 Oct 2026
Beijing Qinghui Liannuo Biotechnology Co Ltd.

Beijing Qinghui Liannuo Biotechnology Co Ltd.

Startups
| Private Company|2018|Beijing Shi, China|
www.unicetbio.com

Overview

Tags

Neoplasms
Nervous System Diseases
Other Diseases
Universal CAR-T
Small molecule drug
γ-δT

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms10
Nervous System Diseases4
Immune System Diseases3
Infectious Diseases3
Hemic and Lymphatic Diseases2
Top 5 Drug TypeCount
Universal CAR-T4
Small molecule drug3
γ-δT3
Antibody1
gamma delta (γδ) T cell engager1
Top 5 TargetCount
CD276(CD276 antigen)3
BTN3A1(butyrophilin subfamily 3 member A1)2
BCMA x CD191
CD19(B-lymphocyte antigen CD19)1

Related

10
Drugs associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
QH104
Target
CD276
Mechanism
CD276 modulators [+2]
Active Org.
The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital) [+1]
Originator Org.
Beijing Qinghui Liannuo Biotechnology Co Ltd.Beijing Qinghui Liannuo Biotechnology Co Ltd.
 [+1]
Active Indication
Glioblastoma Multiforme [+3]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
QH-103
Target
CD19
Mechanism
CD19 inhibitors [+1]
Active Org.
Huazhong University of Science Tongji Hospital, Tongji Medical CollegeHuazhong University of Science Tongji Hospital, Tongji Medical College [+4]
Originator Org.
Anhui Provincial HospitalAnhui Provincial Hospital
Active Indication
Antiphospholipid Syndrome [+25]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
QH101
Target-
Mechanism-
Active Org.
Beijing Qinghui Liannuo Biotechnology Co Ltd.Beijing Qinghui Liannuo Biotechnology Co Ltd.
 [+1]
Originator Org.
Beijing Qinghui Liannuo Biotechnology Co Ltd.Beijing Qinghui Liannuo Biotechnology Co Ltd.
Active Indication
Myelodysplastic Syndromes [+3]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
CTR20254427
/ RecruitingPhase 1
一项评估QH104A细胞注射液在复发或进展的中枢神经系统恶性肿瘤患者中的安全性、耐受性和初步疗效的单臂、开放标签的I期临床研究
[Translation] A single-arm, open-label phase I clinical study evaluating the safety, tolerability, and preliminary efficacy of QH104A cell injection in patients with recurrent or progressive central nervous system malignancies.
100 Clinical Results associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
Login to view more data
0 Patents (Medical) associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
Login to view more data
100 Deals associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
Login to view more data
100 Translational Medicine associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
5
Preclinical
Phase 1
2
1
Phase 2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
QH104A
 ( CD276 )		Meningioma
More
Phase 1
QH-103
 ( CD19 )		Autoimmune Diseases
More
Early Phase 1
QH104
 ( CD276 )		High grade glioma
More
IND Approval
QH101
Solid tumor
More
Preclinical
QH402
Neoplasms
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free